Liberty Health Sciences Comments on CSA Staff Notice

Liberty Health Sciences (CSE:LHS; OTCQX:LHSIF) provided a management commentary after the Canadian Securities Administration’s recent staff notice regarding marijuana activities in the US.

As quoted in the press release:

George Scorsis, Director and CEO of Liberty, announced today that, “We applaud the CSA for affirming and expanding upon their disclosure-based approach, originally announced in October 2017. This updated response reinforces Liberty’s approach to the U.S. medical cannabis market while reducing the existing uncertainty and allowing for ongoing capital market support. We endorse an approach that requires enhanced risk disclosure to inform the capital markets and all stakeholders. We are proud to say that Liberty abides by the requirements and will continue to fulfill all of its obligations under the revised Notice”.

Liberty is a licensed medical cannabis company that adheres to the laws in the U.S. states in which it operates. The Company will continue to focus on their aggressive growth plans in the U.S. medical cannabis market. These growth plans will only focus on those states where a robust legal regime exists for medical cannabis. In addition, the Company will also continue to work with their governmental advisors at the U.S. federal level to provide assistance to governmental officials with the ongoing U.S. policy-making initiatives related to medical cannabis in the United States.

Click here to read the full press release.

Source: www.newswire.ca